Friday, January 14, 2022 Daily Archives

With acquisitions integrated, Curia unveils mRNA offering

by

CDMO Curia is leveraging recent acquisitions to offer end-to-end messenger RNA (mRNA) services, saying COVID-19 vaccines essentially served as proof of concept for the new modality. 2021 was an eventful year for contract development and manufacturing organization (CDMO) Curia. Along with a rebrand from its AMRI heritage, the company acquired LakePharma and Integrity Bio and – having integrated the entities into its business – has now launched a full mRNA service for its customers. “Curia has combined more than 30…

January 14, 2022

Performance Cell acquired by PE, renamed Cellipont Bioservices

by

San Diego CDMO Performance Cell Manufacturing has been acquired by private equity firm Great Point Partners and will operate as Cellipont Bioservices.   Performance Cell Manufacturing (PCM), a contract development and manufacturing organization (CDMO) that has manufactured cell therapies for more than fifteen years, has been acquired by Great Point Partners (GPP) for an undisclosed fee. This is the latest move in a series of CDMO investments by GPP, which includes Cytovance Biologics, MaSTherCell (later acquired by Catalent in February…

January 14, 2022